Cover Image
市場調查報告書

全球肝炎治療藥市場、臨床試驗的考察

Global Hepatitis Drug Market & Clinical Trials Insight 2023

出版商 KuicK Research 商品編碼 518924
出版日期 內容資訊 英文 550 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球肝炎治療藥市場、臨床試驗的考察 Global Hepatitis Drug Market & Clinical Trials Insight 2023
出版日期: 2017年06月23日 內容資訊: 英文 550 Pages
簡介

本報告提供全球肝炎治療藥市場相關調查分析,市場概要,可利用的治療藥,市場分析,臨床實驗平台,上市產品,未來預測相關的系統性資訊。

第1章 關於肝炎

  • 序文
  • 成為肝炎原因的病毒種類

第2章 全球肝炎的盛行率

第3章 肝炎治療可利用的藥物分類

  • 干擾素α
  • 蛋白分解酵素抑制劑
  • 聚合酵素抑制劑
  • 類鐸受體激動劑

第4章 全球肝炎治療藥市場分析

  • 簡介
  • 市場考察

第5章 全球肝炎治療藥市場動態

  • 有利的市場參數
  • 市場課題

第6章 肝炎治療藥的未來發展預測

第7章 全球肝炎治療藥的臨床實驗平台概要

  • A型肝炎
  • B型肝炎
  • C型肝炎
  • D型肝炎
  • E型肝炎

第8章 A型肝炎治療藥的臨床試驗的考察:各相位,各藥物分類

  • 研究
  • 前臨床
  • 臨床
  • 第三階段

第9章 已上市的A型肝炎治療藥臨床考察:各藥物分類

第10章 B型肝炎治療藥的臨床試驗的考察:各相位,各藥物分類

第11章 已上市的B型肝炎治療藥臨床考察:各藥物分類

第12章 C型肝炎治療藥的臨床試驗的考察:各相位,各藥物分類

第13章 已上市的C型肝炎治療藥臨床考察:各藥物分類

第14章 D型肝炎治療藥的臨床試驗的考察:各相位,各藥物分類

第15章 E型肝炎治療藥的臨床試驗的考察:各相位,各藥物分類

第16章 已上市的E型肝炎治療藥臨床考察:各藥物分類

第17章 複數的肝炎治療藥的臨床試驗的考察:各相位,各藥物分類

第18章 已上市的複數的肝炎治療藥臨床考察:各藥物分類

第19章 競爭情形

  • Arbutus Biopharma
  • Biostar Pharmaceuticals
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Gilead Sciences
  • Enanta
  • Achillion
  • Presidio
  • Benitec Biopharma
  • Janssen Pharmaceuticals
  • AbbVie
  • Merck
  • Novira Therapeutics
  • Contravir
  • VBI Vaccines
目錄

"Global Hepatitis Drug Market & Clinical Trials Insight 2023" report gives comprehensive insight on various clinical and non-clinical advancements in the global Hepatitis drug market. Currently, there are 321 Hepatitis drugs in clinical pipeline and 110 Hepatitis drugs are commercially available in the market. Hepatitis drug clinical trials landscape is dominated by Hepatitis C drug with 145 drugs in various phases of development and 25 drugs commercially available in the market. The overall Hepatitis drug revenues are expected to surpass US$ 70 Billion by 2023 with major share accounted by Hepatitis C drugs.

"Global Hepatitis Drug Market & Clinical Trials Insight 2023" report highlights:

  • Prevalence of Hepatitis Infection
  • Available Drug Classes for Hepatitis Drug
  • Global Hepatitis Drug Market Analysis
  • Global Hepatitis (A,B,C,D & E) Drug Clinical Pipeline Insight
  • Marketed Hepatitis Drug Clinical Insight by Drug Class
  • Future Perspective of Hepatitis Therapeutics

Hepatitis virus infection lies among primary public health threats globally and is basically a main reason for the development of liver cirrhosis and hepatocellular carcinoma. The incidence and prevalence of hepatitis viral infection is growing and increases the burden. However, the worldwide remains unknown due to heterogeneous registration and case definitions. There are several subcategories of viruses which cause the infection or inflammation to liver and these subgroups are hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus. The investigation for other subcategory of viruses is ongoing. Hepatitis B virus and hepatitis C virus are main leading causes of liver diseases.

The past two decades have witnessed substantial progress in the treatment of hepatitis virus infection and it includes the introduction of nucleotides and nucleoside analogues, interferons, toll like receptors and protease inhibitors which revolutionized the hepatitis disease management.

With the recent dramatic progress in development of potent antiviral drugs for chronic hepatitis virus infection, virological responses are achievable in almost all patients. Most clinical practice guidelines strongly recommended the treatment of patients with antiviral agents if they have proper indications. The main aim of antiviral treatment is to inhibit the hepatitis virus replication and improve the liver pathology but it rarely cures chronic hepatitis infection.

The global hepatitis drug market is expected to surpass USD 70 Billion by 2023 with the rising number of infected population, growing consumption of alcohol and drugs and the improvement in the access to hepatitis medicines. The introduction of generic drugs of hepatitis has also changed the market dynamics across the globe. With the increase of people being able to afford the generic versions, the usage rates of drugs are expected to grow rapidly over the next few years.

Table of Contents

1. Introduction to Hepatitis Disease

  • 1.1 Prologue
    • 1.1.1 History of Hepatitis
    • 1.1.2 Causes of Hepatitis Disease
  • 1.2 Types of Viruses which are Responsible for Hepatitis Disease

2. Global Prevalence of Hepatitis Infection

3. Available Drug Classes for Hepatitis Disease Treatment

  • 3.1 Interferon Alfa Therapy
  • 3.2 Protease Inhibitors Therapy
  • 3.3 Polymerase Inhibitors Therapy
  • 3.4 Toll like Receptor Agonists Therapy

4. Global Hepatitis Drug Market Analysis

  • 4.1 Introduction
  • 4.2 Global Hepatitis Drug Market Insight

5. Global Hepatitis Drug Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Market Challenges

6. Future Perspective of Hepatitis Therapeutics

7. Global Hepatitis Drug Clinical Pipeline Overview

  • 7.1 Hepatitis A
  • 7.2 Hepatitis B
  • 7.3 Hepatitis C
  • 7.4 Hepatitis D
  • 7.5 Hepatitis E

8. Hepatitis A Drug Clinical Trials Insight by Phase & Drug Class (5 Drugs)

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Clinical
  • 8.4 Phase-III

9. Marketed Hepatitis A Drug Clinical Insight by Drug Class (12 Drugs)

10. Hepatitis B Drug Clinical Trials Insight by Phase & Drug Class (134 Drugs)

  • 10.1 Unknown
  • 10.2 Research
  • 10.3 Preclinical
  • 10.4 Clinical
  • 10.5 Phase-I
  • 10.6 Phase-I/II
  • 10.7 Phase-II
  • 10.8 Phase-II/III
  • 10.9 Phase-III
  • 10.10 Preregistration
  • 10.11 Registered

11. Marketed Hepatitis B Drug Clinical Insight by Drug Class (46 Drugs)

12. Hepatitis C Drug Clinical Trials Insight by Phase & Drug Class (145 Drugs)

  • 12.1 Unknown
  • 12.2 Research
  • 12.3 Preclinical
  • 12.4 Clinical
  • 12.5 Phase-I
  • 12.6 Phase-I/II
  • 12.7 Phase-II
  • 12.8 Phase-II/III
  • 12.9 Phase-III
  • 12.10 Preregistration
  • 12.11 Registered

13. Marketed Hepatitis C Drug Clinical Insight by Drug Class (25 Drugs)

  • 13.1 ZEPATIER
  • 13.2 Harvoni
  • 13.3 Victrelis
  • 13.4 Copegus
  • 13.5 Sovaldi
  • 13.6 Vanihep
  • 13.7 Incivek
  • 13.8 Olysio
  • 13.9 VIEKIRA
  • 13.10 Infergen
  • 13.11 Viekirax
  • 13.12 Epclusa
  • 13.13 Ximency
  • 13.14 Daclatasvir + Asunaprevir Combination
  • 13.15 Peginterferon Alfa-2b (Y-shaped pegylation)
  • 13.16 Golotimod
  • 13.17 Algeron
  • 13.18 Pegetron
  • 13.19 Rebetron
  • 13.20 IBAVYR
  • 13.21 Reiferon Retard
  • 13.22 Reiferon - Interferon Alpha-2a Biosimilar
  • 13.23 Interferon Alpha-2a
  • 13.24 Glycyron Tablets
  • 13.25 Daklinza

14. Hepatitis D Drug Clinical Trials Insight by Phase & Drug Class (4 Drugs)

  • 14.1 Research
  • 14.2 Preclinical
  • 14.3 Phase-II

15. Hepatitis E Drug Clinical Trials Insight by Phase & Drug Class ( 2 Drugs)

  • 15.1 Preclinical
  • 15.2 Phase-I

16. Marketed Hepatitis E Drug Clinical Insight by Drug Class (1 Drug)

17. Multiple Hepatitis Drug Clinical Trials Insight by Phase & Drug Class (31 Drugs)

  • 17.1 Unknown
  • 17.2 Research
  • 17.3 Preclinical
  • 17.4 Clinical
  • 17.5 Phase-I
  • 17.6 Phase-I/II
  • 17.7 Phase-II
  • 17.8 Preregistration

18. Marketed Multiple Hepatitis Drug Clinical Insight by Drug Class (26 Drugs)

19. Competitive Landscape

  • 19.1 Arbutus Biopharma
  • 19.2 Biostar Pharmaceuticals
  • 19.3 Bristol-Myers Squibb
  • 19.4 GlaxoSmithKline
  • 19.5 Gilead Sciences
  • 19.6 Enanta
  • 19.7 Achillion
  • 19.8 Presidio
  • 19.9 Benitec Biopharma
  • 19.10 Janssen Pharmaceuticals
  • 19.11 AbbVie
  • 19.12 Merck
  • 19.13 Novira Therapeutics
  • 19.14 Contravir
  • 19.15 VBI Vaccines

List of Figures

  • Figure 1-1: Pathogenesis of Liver by the Exposure of Different Factors
  • Figure 1-2: Historical Development of Hepatitis Drug Treatment
  • Figure 1-3: Factors which are Responsible for Hepatitis Disease Development
  • Figure 2-1: Global - Incidence & Mortality Cases of Hepatitis B Infection (Million), 2015
  • Figure 2-2: Global - Incidence & Mortality Cases of Hepatitis C Infection (Million), 2015
  • Figure 3-1: Interferon Alpha - Mechanism of Action for Treating Liver Disease
  • Figure 3-2: Toll like Receptors & Activation of Antiviral Innate and Adaptive Immune Responses in Hepatitis Virus Infection
  • Figure 4-1: Global- Hepatitis B & C as Cause for Liver Cancer (%)
  • Figure 4-2: Global - Hepatitis Drug Market (US$ Billion), 2016 - 2023
  • Figure 4-3: Global- Hepatitis B Drug Market (US$ Billion), 2016-2023
  • Figure 4-4: Global - Hepatitis C Drug Market (US$ Billion), 2016-2023
  • Figure 5-1: Favorable Parameters to Hepatitis Drug Treatment Market Growth
  • Figure 5-2: Challenges to Hepatitis Therapeutic Market Growth
  • Figure 6-1: Future Landscape of Hepatitis Infection Treatment Research
  • Figure 7-1: Global - Hepatitis A Drug Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 7-2: Global - Hepatitis A Drug Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 7-3: Global - Hepatitis B Drug Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 7-4: Global - Hepatitis B Drug Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 7-5: Global Hepatitis C Drug Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 7-6: Global Hepatitis C Drug Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 7-7: Global - Hepatitis D Drug Clinical Pipeline By (%), 2017 till 2023
  • Figure 7-8: Global - Hepatitis D Drug Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 7-9: Global - Hepatitis E Drug Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 7-10: Global - Hepatitis E Drug Clinical Pipeline by Phase (Number), 2017 till 2023

List of Tables

  • Table 3-1: Protease Inhibitors in Development for Hepatitis Disease Treatment
  • Table 3-2: Toll like Receptor Affecting Immunopathogenesis of Hepatitis Virus Infection
Back to Top